Objectives Determine factors affecting survival rates, benefits and complications of patients with obstructive esophageal cancer treated with photodynamic therapy (PDT (median 5.0mm) This was statistically significant using paired t-tests (p < 0.0001).
INTRODUCTION
The use of selective photodynamic therapy (PDT) to treat malignant tumors is based on three observations: (1) after being injected intravenously, the photosensitizer disseminates to all cells; (2) due to differences in vascular and lymphatic clearance from tumors, and retention of the photosensitizer by the tumor cells, the photosensitizer is selectively retained in the tumor cells and interstitial tissue of the tumor so that after two or three days there is a greater concentration of the photosensitizer in the tumors than in the adjacent normal tissue; (3) the photosensitizer will absorb light energy and produce singlet oxygen which then destroys the tumor. Since there is less photosensitizer in the adjacent tissue, it will react less. We report here our experience using PDT to treat patients with obstructive esophageal cancer.
MATERIALS AND METHODS
In a prospective study from 1982 to January 1998 we used PDT to treat 140 patients with obstructive esophageal carcinoma and evaluated their survival up to November 1998. Entry criteria were a histologic diagnosis of adeno or squamous cell carcinoma of the esophagus and failure of conventional treatment or ineligibility for them because of medical status. There was 100% follow up. Their Photodynamic therapy was performed using 630 nm light generated by either an argon dye laser system (Spectra Physics) or a double frequency YAG-dye laser system (Laserscope) as the activator and delivered through cylinder diffusing tip quartz fibers passed through the biopsy channel of a flexible endoscope. When possible the diffuser tip was inserted into the tumor. Otherwise, it was placed along side of the tumor.
Initial treatments were performed using hematoporphyrin derivative as the photosensitizer but for the last 14 years we have used dihematoporphyrin ether (DHE, Photofrin; Quadra Logic Technologies, Vancouver, B.C.) injected intravenously one to three days before the treatment.
Various photosensitizer doses, day of treatment after injection, light power densities, and light doses were evaluated [3] [4] [5] [6] [7] [8] A repeat esophagoscopy and dilation is done two days after PDT but we rarely retreat at this time. Patients are rescoped one month after PDT and we may retreat at this time without another injection [11] . At this time we use 300J/CF even on the "normal" mucosa.
Comparison of Survival from other Treatment Regimens
In a retrospective analysis ofsurvival from diagnosis of 268 patients with carcinoma of the esophagus Oliver et al. [12] found the overall median survival (months) stratified by primary treatment was: surgery 9.8; radical X-ray 6 Poplin et al. [15] reported on 106 patients with squamous cell carcinoma of the esophagus registered into a study combining preoperative chemotherapy and external radiation with an overall median survival of 12 months and an 11% operative mortality.
LePrise et al. [16] reported preoperative chemotherapy and radiation (CRT) did not change the operative mortality or survival time for patients with Stages I and II squamous cell carcinoma of the esophagus. The operative mortality was 8.5% for CRT and 7% for without CRT. The median survival was 10 months for both groups.
Skinner et al. [17] reported the median survival of those patients chosen for "standard esophagectomy" for palliation because of extensive disease was 8 months.
Law et al. [18] reported median survivals after palliative resection of 7 months for 236 patients with squamous cell and 8 months for 57 patients with adenocarcinoma.
We also treated 33 patients with the YAG laser for esophageal obstruction [8] and compared our results with PDT. PDT is easier to perform than YAG laser treatments. There is less possibility of burning a hole in the tissue with PDT. On occasion, it is impossible to get the YAG laser in position to safely treat the tumor with the YAG because of the anatomy. Cervical lesions are difficult to treat with the YAG laser because one may not be able to keep the endoscope in the esophagus. The [20] [21] [22] [23] [24] .
At [21, 23, 25, 26] . Most Barrett's are caused by acid reflux [27, 28] . Most reflux is due to hiatal hernias [29] [30] [31] [32] . Overholt Cervical lesions are difficult to treat with the YAG laser while the PDT diffuser tip can be inserted and the treatment performed blindly. PDT also treats submucosal spread that is not visible and can be used to treat small mammary-like tumors. Debulking large tumors and treating the residual tumor with PDT utilizes the advantages of both techniques. Palliation with PDT compares favorably to surgery for "non-curative" disease. PDT can be used concomitantly with chemotherapy and X-ray irradiation and can be repeated indefinitely. Photosensitivity of the skin to solar irradiation due to the photosensitizer is more of a nuisance than a serious problem for most of these patients.
